|
|
Volumn 33, Issue 3, 2015, Pages 217-218
|
|
$1-million price tag set for Glybera gene therapy
a
a
NONE
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALIPOGENE TIPARVOVEC;
AMYOTROPHIC LATERAL SCLEROSIS;
BETA THALASSEMIA;
DRUG APPROVAL;
DRUG COST;
DRUG INDUSTRY;
EUROPEAN MEDICINES AGENCY;
FOOD AND DRUG ADMINISTRATION;
FRIEDREICH ATAXIA;
HEMATOPOIETIC STEM CELL;
HUMAN;
HUNTINGTON CHOREA;
NOTE;
PARKINSON DISEASE;
PRIORITY JOURNAL;
RETINA DYSTROPHY;
SICKLE CELL ANEMIA;
VIRAL GENE THERAPY;
ADVERSE EFFECTS;
COMMERCIAL PHENOMENA;
ECONOMICS;
EUROPE;
GENE THERAPY;
HEALTH INSURANCE;
TREATMENT OUTCOME;
UNITED STATES;
COMMERCE;
DRUG INDUSTRY;
EUROPE;
GENETIC THERAPY;
HUMANS;
INSURANCE, HEALTH;
TREATMENT OUTCOME;
UNITED STATES;
|
|
EID: 84924404163
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0315-217 Document Type: Note |
|
Times cited : (84)
|
|
References (0)
|
